News stories about LeMaitre Vascular (NASDAQ:LMAT) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. LeMaitre Vascular earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news articles about the medical instruments supplier an impact score of 45.1568822354599 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

A number of brokerages have recently commented on LMAT. Zacks Investment Research downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Thursday, September 28th. Canaccord Genuity cut their price objective on LeMaitre Vascular from $30.00 to $29.00 and set a “hold” rating for the company in a research report on Friday, October 27th. First Analysis downgraded shares of LeMaitre Vascular from an “overweight” rating to an “equal weight” rating and set a $34.00 target price on the stock. in a research note on Friday, October 27th. Benchmark downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, October 27th. Finally, BidaskClub downgraded shares of LeMaitre Vascular from a “hold” rating to a “sell” rating in a research note on Saturday, December 2nd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $32.20.

Shares of LeMaitre Vascular (NASDAQ LMAT) traded up $1.24 during trading hours on Friday, reaching $31.96. 106,800 shares of the company’s stock traded hands, compared to its average volume of 124,613. LeMaitre Vascular has a 52 week low of $19.82 and a 52 week high of $39.88. The firm has a market cap of $607.97, a P/E ratio of 40.97, a P/E/G ratio of 2.36 and a beta of 0.54.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.05. LeMaitre Vascular had a net margin of 15.81% and a return on equity of 16.16%. The company had revenue of $24.80 million for the quarter, compared to the consensus estimate of $25.49 million. During the same period in the previous year, the business earned $0.17 EPS. The company’s revenue was up 6.9% on a year-over-year basis. equities analysts anticipate that LeMaitre Vascular will post 0.84 earnings per share for the current fiscal year.

In other LeMaitre Vascular news, insider David B. Roberts sold 4,123 shares of the business’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $32.14, for a total transaction of $132,513.22. Following the sale, the insider now directly owns 24,482 shares of the company’s stock, valued at approximately $786,851.48. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 23.70% of the stock is owned by insiders.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-lemaitre-vascular-lmat-stock-price/1804391.html.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Insider Buying and Selling by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with Analyst Ratings Network's FREE daily email newsletter.